Stocks to sell

The U.S. public and the market are belatedly realizing that the Delta variant of the coronavirus is not very dangerous, especially to those who are vaccinated and won’t stay in the U.S. for many months. Consequently, now is not a good time to buy highly valued stocks that thrive when consumers stay at home more.

This is certainly an odd economy. On one hand, the delta variant is a dark shadow over how long economic expansion lasts. On the other, the economy is booming and oil stocks have gone from zeros to heroes in the past year. The S&P Global Oil Index, which measures the performance of 120 of the

DiDi Global (NYSE:DIDI) could easily fall quite significantly to the value of just its non-China operations, plus its net cash (as long as that cash is not in China). This is because Chinese regulators have placed the company under dire restrictions. If that happens, I estimate that DIDI stock would be worth no more than

Right now everyone loves Square (NASDAQ:SQ) stock. Source: Jonathan Weiss / Shutterstock.com The company only came public in 2015, at a market cap of $2.9 billion. Today that number is right around $124 billion. At its current value Square is the third most valuable payment outfit, behind only MasterCard (NYSE:MA) and Visa (NYSE:V). But it

How far can a small medical devices company take a celebrity endorsement? The shares of veterinary diagnostics company Zomedica (NYSEAMERICAN:ZOM) surged after an endorsement from Tiger King celebrity Carole Baskin. In response, meme traders bid ZOM stock up sharply. Since the short interest in ZOM stock is high, the news created a dramatic short squeeze. Source:

Clover Health (NASDAQ:CLOV) has been one of the year’s biggest disappointments. The so-called King of SPACs (special purpose acquisition companies), Chamath Palihapitiya, took the health insurer public via one of his Social Capital Hedosophia SPACs. CLOV stock shares almost immediately tumbled after short sellers revealed that it had failed to disclose a government investigation into

Outlier Covid-19 vaccine play Ocugen (NASDAQ:OCGN) stock has been on a negative run in the past three months, losing about 17% of its value. Source: Shutterstock The company failed to gain an emergency use authorization (EUA) from the FDA for Covaxin, the Indian variant of the coronavirus vaccine. Moreover, its partner firm Bharat Biotech is

If you think Carnival (NYSE:CCL) and CCL stock is a good bet at almost $24, you might want to think again. Covid-19 is still very much still an “unwanted passenger” on its cruise ships. As a result, a resumption to pre-pandemic cruising — as well as improvements in the CCL stock price — seem like they’re

This is my first time writing about Novavax (NASDAQ:NVAX) and the more I learn about the company, I can’t help but think about Inception, the Leonardo DiCaprio movie about dreams within dreams. A lot of the discussion around Novavax’s Covid-19 vaccine feels like living in that film’s impossible dream worlds. People buying NVAX stock are believing

Tilray (NASDAQ:TLRY) stock has become one of the biggest cannabis names following the Aphria-Tilray business combination. Source: Jarretera / Shutterstock.com The newly combined company now has a much greater chance at carving out a piece of the U.S. market following the deal.  But the company is also currently making headlines in regard to other deal

GameStop (NYSE:GME) remains one of the year’s most remarkable stock market stories. GME stock enjoyed not one but two historic short squeezes, leading to windfall profits for longs and incredible pain for skeptics such as Melvin Capital. Source: rblfmr / Shutterstock.com However, the fun may be winding down for GameStop. Shares have been sliding for

With poor financial results, declining market share and no access to the U.S. market, Canadian cannabis producer Canopy Growth (NASDAQ:CGC) stock remains difficult to bet on. Source: Shutterstock CGC stock is down 33% so far this year and the slide shows no signs of ending anytime soon. At $17.47, the company’s shares are now at

Cassava Sciences (NASDAQ:SAVA) is a biotech company with an important goal: fighting Alzheimer’s disease. It has several treatments in development, but is SAVA stock worth adding to your portfolio? Source: Shutterstock Obviously, I want this company to succeed; I witnessed a family friend’s battle with Alzheimer’s disease, and I would love for Cassava to succeed

AT&T (NYSE:T) announced on May 17 that it would spin-off its WarnerMedia subsidiary and merge it with Discovery Communications (NASDAQ:DISCA, NASDAQ:DISCB, NASDAQ:DISCK) to create another massive media conglomerate. T stock has lost 13% of its value in the three months since.  Source: Shutterstock In 2021, AT&T’s stock has traded below $30 for all but a

A spate of positive developments may be helping to keep AMC Entertainment (NYSE:AMC) stock steady. But should investors take this as a sign that it’s wise to buy in now, ahead of this “meme stock” favorite of the Reddit trading community surging higher once again? Source: viewimage / Shutterstock.com Not so fast. Its recent resiliency

Stock market gauges such as the S&P 500 index and Nasdaq 100 index continue to sit at or near all-time highs. While leading stocks continue to perform admirably, many companies have had a difficult summer. Small-cap firms, special purpose acquisition companies (SPACs), and unprofitable tech companies have seen their shares dive. If the corrections spread,

A cryptic hand gesture by Lucid Motors (NASDAQ:LCID) CEO Peter Rawlinson (made twice!) has Twitter (NYSE:TWTR) on fire as investors begin to speculate what it could mean. Source: Lucid Motors Rawlinson was photographed at two recent Lucid press events playfully throwing up four fingers. Not quite a TikTok-friendly “Sheesh,” but many are interpreting his hand

Private company space wars seemed like science fiction just 10 or 20 years ago, but are now coming to fruition as multiple competitors gear up for the new race for space dominance. Jeff Bezos’s Blue Origin and Elon Musk’s SpaceX are among the leaders in the field. But one of the early innovators in this

Value investors are at a loss to explain the performance of Alibaba (NYSE:BABA) stock. Holding BABA stock in the hopes that the shares can return to their 52-week high may prove to be unprofitable. Source: BigTunaOnline / Shutterstock.com That’s because China’s government is introducing stricter regulations in many sectors. So despite paying a $2.75 billion

Although I’m a car enthusiast, I’m not in love with Nio (NYSE:NIO) stock. In fact, I’ve repeatedly suggested that investors avoid it in the past. Source: xiaorui / Shutterstock.com In 2020 I wrote the article “Nio Stock Has Skyrocketed in 2020, But High Risks Remain” using the Nasdaq Dozen method to analyze the company, I focused

A month ago I wrote that Uber (NYSE:UBER) was likely to fall 20% from $49.07 on July 9, and not rise over 42% like other analysts were saying. Since then, UBER stock has dropped over 17% to below $40 and is still falling. Source: NYCStock / Shutterstock.com I suspect that, given another lousy loss-making quarter by

A week after a disappointing earnings report sent shares of ContextLogic (NASDAQ:WISH) plunging almost 21%, WISH stock hovers just above its 12-month low of $6.14 a share. Source: sdx15 / Shutterstock.com At one point on Aug. 13, shares were down 28.9% from the previous day’s close. The hits kept coming, as one influential analyst said

For the quarter ending May 1, 2021, GameStop (NYSE:GME) was able to reduce its total store count by 12% year-over-year (YoY), according to its first-quarter earnings release. As a result, the company’s losses fell from $165.1 million or $2.65 per share last year to just $66.8 million or $1.01 per share this quarter. This is

The U.S. infrastructure bill has been passed by the Senate. Will this initiative give ChargePoint (NYSE:CHPT) stock a boost? I wouldn’t really count on it. Sure, EV charging companies, including ChargePoint, stand to benefit greatly from this bill. The legislation could give early-stage companies in this industry a shot in the arm as they grow into

I have always wondered about why the memesters decided they liked Clover Health (NASDAQ:CLOV) stock. Source: Shutterstock Maybe it was the short squeeze, which came after Hindenburg Research issued a February report calling the business broken. Maybe it was Chamath Palihapitiya, whom I have likened to Prof. Harold Hill of The Music Man. (Full disclosure:

Exela Technologies (NASDAQ:XELA) is a Texas company that sells itself as a leader in business process automation. The XELA stock price is down 8.6% in the last six months. Source: Alextype/Shutterstock.com The current company is the result of a 2017 tie-up of three companies which now suffers from crushing debts. Exela is still around thanks to

“The pill that moves the needle.” This is the statement highlighted on Vaxart’s (NASDAQ:VXRT) website, and it is written to make a bold impression. Recently, the company has been in the spotlight for its Covid-19 vaccine that is notably in pill form. Its inoculation isn’t ready yet, but some investors have already picked up shares

It hasn’t been a fun ride for Workhorse (NASDAQ:WHKS) stock. Source: rblfmr / Shutterstock.com In fact, most start-up EV, low-quality special purpose acquisition companies (SPACs) and high-growth stocks have struggled over the past few months. In the case of WKHS stock, shares remain 76% below the all-time high set in February. Unfortunately for Workhorse, earnings aren’t

Clover Health Investments (NASDAQ:CLOV) recently reported second quarter revenue and earnings on Aug 11. The numbers showed a huge gain in revenue but an equally huge increase in its losses. This does not bode well for CLOV stock. Source: Shutterstock Additionally, Clover significantly raised its total 2021 revenue outlook from $820 million at the midpoint last quarter

Ever since Nano Dimension (NASDAQ:NNDM) peaked in Feb. 2021 and trended lower, Meta Materials (NASDAQ:MMAT) stock followed. Source: BLAGORODEZ / Shutterstock.com On Aug. 5, Meta Materials announced an indirect acquisition of Nanotech Security for CAD 90.8 million. Meta, whose technology platform delivers highly functional and sustainable materials, wants Nanotech for its authentication and brand protection